NCT05999396View on ClinicalTrials.gov

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

March 31, 2027

Conditions
Colorectal CancerBreast CarcinomaSarcomaPenile Carcinoma
Interventions
DRUG

Administration of CC-3

Accelerated titration phase, Standard 3+3 titration phase, expansion phase

Trial Locations (1)

72076

RECRUITING

University Hospital Tuebingen, Tübingen

All Listed Sponsors
lead

German Cancer Research Center

OTHER